

REMARKS

In the Office Action of April 6, 2007, a restriction requirement was presented: Group I – Claims 63-71 and Group II – Claim 72. Applicant elects Group II with traverse. It is believed that the searching of the claims as pending would be no more burdensome than the searching for Claims 63-71.

Applicant has canceled claims 63 to 71 without prejudice on the basis of the election made under the restriction requirement, specifically reserving the right to file any subsequent application over said subject matter. Applicant further requests rejoinder as discussed in the restriction requirement with the understanding that the process claims must recite the limitations of the allowable product claims.

It is believed that a call was placed to the Examiner by an attorney previously handling this case to verify that nothing other than a response to the pending restriction requirement is needed for a complete response.

SUPPORT FOR AMENDMENTS

Support for the amendments is found at least in the claims as filed and also please see: page 3, lines 14-26; page 5, and page 6 spanning to page 7, line 12.

CONCLUSION

Applicants believe that the claims are in order for allowance, early notice of which is requested. If Examiner has any questions concerning this application, Examiner is invited to contact the below-signed attorney. A fee is due. Please charge any payment or credit any overpayment to Charge Account 16-1445.

Respectfully submitted,

Dated: 3 August 2007

/Mary J. Hosley/
Mary Hosley, Registry No. 48,324
Attorney for Applicants

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
Phone (212)733-0460
Fax (212) 573-1939